Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | elongation factor Tu | 0.0008 | 0.0301 | 0.5 |
Plasmodium vivax | elongation factor Tu, mitochondrial precursor, putative | 0.0008 | 0.0301 | 0.0301 |
Trichomonas vaginalis | sulfate adenylyltransferase subunit, putative | 0.0008 | 0.0301 | 0.0301 |
Schistosoma mansoni | elongation factor tu (ef-tu) | 0.0008 | 0.0301 | 0.0301 |
Echinococcus multilocularis | elongation factor 1 alpha | 0.0045 | 1 | 1 |
Echinococcus granulosus | elongation factor 1 alpha | 0.0045 | 1 | 1 |
Mycobacterium leprae | PROBABLE IRON-REGULATED ELONGATION FACTOR TU TUF (EF-TU) | 0.0008 | 0.0301 | 0.5 |
Trichomonas vaginalis | elongation factor 1-alpha, putative | 0.0043 | 0.9691 | 0.9691 |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 0.9991 | 0.9991 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Loa Loa (eye worm) | elongation factor Tu1 | 0.0008 | 0.0301 | 0.0301 |
Schistosoma mansoni | hypothetical protein | 0.0008 | 0.0301 | 0.0301 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Onchocerca volvulus | 0.0045 | 1 | 0.5 | |
Giardia lamblia | Elongation factor 1-alpha | 0.0045 | 1 | 1 |
Echinococcus multilocularis | g1 to s phase transition protein | 0.0008 | 0.0301 | 0.0301 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Giardia lamblia | Elongation factor 1-alpha | 0.0045 | 1 | 1 |
Echinococcus multilocularis | elongation factor tu (ef tu) | 0.0008 | 0.0301 | 0.0301 |
Wolbachia endosymbiont of Brugia malayi | elongation factor Tu | 0.0008 | 0.0301 | 0.5 |
Plasmodium falciparum | elongation factor Tu, putative | 0.0008 | 0.0301 | 0.0301 |
Trypanosoma brucei | EF-1-alpha | 0.0008 | 0.0301 | 0.0301 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Schistosoma mansoni | elongation factor tu (ef-tu) | 0.0008 | 0.0301 | 0.0301 |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Onchocerca volvulus | 0.0045 | 1 | 0.5 | |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Loa Loa (eye worm) | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Plasmodium falciparum | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Trichomonas vaginalis | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Trypanosoma brucei | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Toxoplasma gondii | elongation factor 1-alpha (EF-1-ALPHA), putative | 0.0045 | 1 | 1 |
Loa Loa (eye worm) | eukaryotic translation elongation factor 1A | 0.0045 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | elongation factor Tu | 0.0008 | 0.0301 | 0.5 |
Entamoeba histolytica | elongation factor 1-alpha 1 | 0.0045 | 1 | 1 |
Toxoplasma gondii | elongation factor tu, apicoplast, putative | 0.0008 | 0.0301 | 0.0301 |
Toxoplasma gondii | elongation factor 1-alpha (EF-1-ALPHA), putative | 0.0045 | 1 | 1 |
Trypanosoma brucei | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Echinococcus granulosus | elongation factor tu ef tu | 0.0008 | 0.0301 | 0.0301 |
Trypanosoma brucei | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Entamoeba histolytica | elongation factor 1-alpha 1 | 0.0045 | 1 | 1 |
Loa Loa (eye worm) | elongation factor Tu domain-containing protein | 0.0008 | 0.0301 | 0.0301 |
Schistosoma mansoni | elongation factor 1-alpha (ef-1-alpha) | 0.0008 | 0.0292 | 0.0292 |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Echinococcus granulosus | g1 to s phase transition protein | 0.0008 | 0.0301 | 0.0301 |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Schistosoma mansoni | elongation factor 1-alpha (ef-1-alpha) | 0.0045 | 1 | 1 |
Mycobacterium ulcerans | elongation factor Tu | 0.0008 | 0.0301 | 0.5 |
Leishmania major | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Trichomonas vaginalis | translation factor, putative | 0.0045 | 1 | 1 |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Entamoeba histolytica | elongation factor 1-alpha 1 | 0.0045 | 1 | 1 |
Leishmania major | elongation factor Tu, putative | 0.0008 | 0.0301 | 0.0301 |
Brugia malayi | elongation factor 1-alpha (EF-1-alpha) | 0.0045 | 1 | 1 |
Plasmodium falciparum | elongation factor Tu | 0.0008 | 0.0301 | 0.0301 |
Chlamydia trachomatis | elongation factor Tu | 0.0008 | 0.0301 | 0.5 |
Toxoplasma gondii | elongation factor Tu, putative | 0.0008 | 0.0301 | 0.0301 |
Plasmodium falciparum | elongation factor 1-alpha | 0.0045 | 1 | 1 |
Brugia malayi | elongation factor Tu homologue precursor | 0.0008 | 0.0301 | 0.0301 |
Brugia malayi | Elongation factor Tu C-terminal domain containing protein | 0.0008 | 0.0301 | 0.0301 |
Trichomonas vaginalis | translation factor, putative | 0.0045 | 0.9991 | 0.9991 |
Plasmodium vivax | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Trypanosoma cruzi | elongation factor 1-alpha, putative | 0.0045 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Agonist activity at human delta opioid receptor expressed in HEK293 cells assessed as induction of intracellular calcium release by FLIPR assay | ChEMBL. | 24978316 | |
Activity (functional) | Agonist activity at human kappa opioid receptor expressed in HEK293 cells assessed as induction of intracellular calcium release by FLIPR assay | ChEMBL. | 24978316 | |
Activity (binding) | Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as induction of intracellular calcium release by FLIPR assay | ChEMBL. | 24978316 | |
Time (functional) | = 20 min | Antinociceptive effect in intrathecally dosed ICR-CD1 mouse assessed as peak time for antinociceptive effect by tail flick test | ChEMBL. | 24978316 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.